UNLABELLED: Polymorphonuclear neutrophils (PMN) play an important role in the pathogenesis of diabetic microvascular complications. Stimulation of these cells is associated with the appearance of specific receptors on their surface. The aim of the study was to evaluate the expression of the receptors specific for PMN: CD 11b, CD 18. The study was performed in a group of 23 type 1 diabetic patients, aged from 19 to 47 years (mean 30.7 +/- 8.6 years), including 15 females and 8 males (mean diabetes duration time 13.7 +/- 7.5 years; mean HbA1c 7.9 +/- 2.5%). The expression of PMN surface receptors was measured by flow cytometry using a ORTHO DIAGNOSTIC SYSTEM cytofluorimeter. The results were presented as a PMN percentage indicating expression of CD 11b and CD 18. In comparison to healthy controls, there was a significant increase in the number of PMN, both with CD 11b and CD 18 receptors present--(CD 11b: 93.2 +/- 3.4 vs 98.0 +/- 1.9% p < 0.05), (CD 18: 98.5 +/- 0.47 vs 99.4 +/- 0.7%, p < 0.05). CONCLUSION: In patients with type 1 diabetes, PMNs demonstrate a pronounced expression of surface receptors which may indicate an enhanced activity of these cells. The increase of expression of surface receptors is independent of diabetes duration time and HbA1c.
UNLABELLED: Polymorphonuclear neutrophils (PMN) play an important role in the pathogenesis of diabetic microvascular complications. Stimulation of these cells is associated with the appearance of specific receptors on their surface. The aim of the study was to evaluate the expression of the receptors specific for PMN: CD 11b, CD 18. The study was performed in a group of 23 type 1 diabeticpatients, aged from 19 to 47 years (mean 30.7 +/- 8.6 years), including 15 females and 8 males (mean diabetes duration time 13.7 +/- 7.5 years; mean HbA1c 7.9 +/- 2.5%). The expression of PMN surface receptors was measured by flow cytometry using a ORTHO DIAGNOSTIC SYSTEM cytofluorimeter. The results were presented as a PMN percentage indicating expression of CD 11b and CD 18. In comparison to healthy controls, there was a significant increase in the number of PMN, both with CD 11b and CD 18 receptors present--(CD 11b: 93.2 +/- 3.4 vs 98.0 +/- 1.9% p < 0.05), (CD 18: 98.5 +/- 0.47 vs 99.4 +/- 0.7%, p < 0.05). CONCLUSION: In patients with type 1 diabetes, PMNs demonstrate a pronounced expression of surface receptors which may indicate an enhanced activity of these cells. The increase of expression of surface receptors is independent of diabetes duration time and HbA1c.